Adcock Ingram at a glance

 

FINANCIAL CAPITAL*

  

INTELLECTUAL CAPITAL
   

Turnover
R6 540m
(2017: R5 936m)

Trading profit
R866m
(2017: R724m)

    

The South African private pharmaceutical
market, as measured by IQVIA MAT
June 2018, is worth R42.9 billion, with
7.1% value and 4.9% volume growth
(including new products).

Adcock Ingram holds a private market
share of 9% in value and 21% in volume.
   

HEPS
387.7c
(2017: 308.9c )

Share price close
6 015c
Low: 4 900c High: 7 200c

    
   

* Continuing operations

        

 

NATURAL CAPITAL

  

MANUFACTURED CAPITAL
 
 

SOCIAL AND RELATIONSHIP CAPITAL
   

B-BBEE SCORE
LEVEL 3
     
 

HUMAN CAPITAL
   

Employees
2 610
     
   

Energy usage (kWh)
50 379m
(2017: 49 456m)

  
BANGALORE
(JV facility)		   Capacity – Tablets
and capsules:
3,5 BILLION UNITS
Accreditations:   Nigeria (NAFDAC),
UK (MHRA),   Ghana (FDB),
Australia (TGA),   Namibia (NMRC),
South Africa (SAHPRA),   Uganda (UNDA),
France (ANSM),   Zimbabwe (MCAZ),
Tanzania (TFDA),   Malawi (PMPB), and
Kenya (PPB),   Ethiopia (FMHACA)
 
   

Carbon emissions**
24.67
(2017: 28.26)

** (Scope 1 and 2) per full-time employee (tonnes).

  
   

Water usage (Kℓ)
271 318
(2017: 281 247)

  

The tablet and capsule facility   The Critical Care facility   The high-volume liquids facility   BEE Certificate
The tablet and capsule facility located in Wadeville is focused primarily on the manufacturing of anti-retroviral medicines.   The Critical Care facility situated in Aeroton produces intravenous fluids, blood bags, renal dialysis products and small-volume parenterals.   The high-volume liquids facility situated in Clayville is a state-of-the-art, highly automated factory primarily producing liquids and effervescent formulations.   Extract from B-BBEE certificate

ACTIVITIES

MANUFACTURING   MANUFACTURING
We have four manufacturing facilities.
     
SALES AND MARKETING   SALES AND MARKETING
Our sales and marketing activities are conducted from our office in Midrand.
     
DISTRIBUTION   DISTRIBUTION
Adcock Ingram has a state-of-the-art distribution system, designed to distribute the Company’s products, as well as those of its contracted partners, direct to all customers.
 

BUSINESS UNITS

OVER THE COUNTER focuses on brands sold predominantly in pharmacy, where the pharmacist plays a role in the product choice and includes brands like Corenza and Citro-Soda.

  

The HOSPITAL portfolio has a long history with Baxter which positions Adcock Ingram as a leading supplier of critical care products, including intravenous solutions, blood collection products and renal dialysis systems.
         

The PRESCRIPTION portfolio comprises products prescribed by medical practitioners and includes a range of quality and affordable generic medicines.

  

CONSUMER competes in the Fast Moving Consumer Goods (FMCG) space and includes market-leading brands such as Panado and Bioplus.

ADCOCK INGRAM HOLDINGS LIMITED

Adock Ingram Holdings Limited